Search results for "Anti-HIV agents"

showing 10 items of 90 documents

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

2014

Background: One out of ten newly diagnosed patients in Europe was infected with a virus carrying a drug resistant mutation. We analysed the patterns over time for transmitted drug resistance mutations (TDRM) using data from the European Spread program.Methods: Clinical, epidemiological and virological data from 4317 patients newly diagnosed with HIV-1 infection between 2002 and 2007 were analysed. Patients were enrolled using a pre-defined sampling strategy.Results: The overall prevalence of TDRM in this period was 8.9% (95% CI: 8.1-9.8). Interestingly, significant changes over time in TDRM caused by the different drug classes were found. Whereas nucleoside resistance mutations remained con…

Malevirus strainResistanceHIV InfectionsDrug resistanceTHERAPYNucleoside Reverse Transcriptase InhibitorANTIRETROVIRAL DRUG-RESISTANCE0302 clinical medicineMedical microbiologyGenotypeMedicine and Health SciencesPrevalenceHIV Infection030212 general & internal medicineUNITED-KINGDOMPhylogeny0303 health sciencesCommunicable diseaseTransmission (medicine)adultvirus mutationUPDATED RECOMMENDATIONSvirus transmission3. Good healthEuropeInfectious Diseasesfemalerisk factorvirus resistanceFemaleNAIVE PATIENTSSOCIETY-USA PANELResearch ArticleHumanAdultmedicine.medical_specialtyGenotypeAnti-HIV AgentsVirusArticle03 medical and health sciencesSDG 3 - Good Health and Well-beingmaleMOLECULAR EPIDEMIOLOGYDrug Resistance Viralmedicineproteinase inhibitorHumansTransmissioncontrolled studyhumanmolecular phylogeny030304 developmental biologynonhumanMUTATIONSbusiness.industryAnti-HIV Agentnucleotide sequencenonnucleoside reverse transcriptase inhibitorHuman immunodeficiency virus 1 infectionVirologymajor clinical studyunindexed sequenceParasitology3121 General medicine internal medicine and other clinical medicineMutationHIV-1business
researchProduct

Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz.

2014

Objectives Growing evidence associates the non-nucleoside reverse transcriptase inhibitor efavirenz with several adverse events. Newer antiretrovirals, such as the integrase inhibitor raltegravir, the non-nucleoside reverse transcriptase inhibitor rilpivirine and the protease inhibitor darunavir, claim to have a better toxicological profile than efavirenz while producing similar levels of efficacy and virological suppression. The objective of this study was to determine the in vitro toxicological profile of these three new antiretrovirals by evaluating their effects on the mitochondrial and cellular parameters altered by efavirenz in hepatocytes and neurons. Methods Hep3B cells and primary …

Microbiology (medical)CyclopropanesEfavirenzAnti-HIV AgentsIntegrase inhibitorBiologyMitochondrionPharmacologychemistry.chemical_compoundCell Line TumorRaltegravir PotassiumDrug Resistance ViralNitrilesmedicineAnimalsHumansPharmacology (medical)DarunavirCells CulturedDarunavirPharmacologyNeuronsSulfonamidesReverse-transcriptase inhibitorRilpivirinemedicine.diseaseRaltegravirPyrrolidinonesBenzoxazinesMitochondriaRatsMitochondrial toxicityInfectious DiseasesPyrimidineschemistryRilpivirineAlkynesHepatocytesReverse Transcriptase Inhibitorsmedicine.drugThe Journal of antimicrobial chemotherapy
researchProduct

Efavirenz and the CNS: what we already know and questions that need to be answered

2015

The NNRTI efavirenz has long been one of the most frequently employed antiretroviral drugs in the multidrug regimens used to treat HIV infection, in accordance with its well-demonstrated antiretroviral efficacy and favourable pharmacokinetics. However, growing concern about its adverse effects has sometimes led to efavirenz being replaced by other drugs in the initial treatment selection or to switching of therapy to efavirenz-free regimens in experienced patients. Neurological and neuropsychiatric reactions are the manifestations most frequently experienced by efavirenz-treated patients and range from transitory effects, such as nightmares, dizziness, insomnia, nervousness and lack of conc…

Microbiology (medical)DrugCentral Nervous SystemCyclopropanesPsychosismedicine.medical_specialtyEfavirenzAnti-HIV Agentsmedia_common.quotation_subjectHIV InfectionsPolymorphism Single Nucleotidechemistry.chemical_compoundimmune system diseasesCentral Nervous System DiseasesAntiretroviral Therapy Highly ActivemedicineAnimalsCytochrome P-450 Enzyme InhibitorsHumansPharmacology (medical)Adverse effectIntensive care medicineSuicidal ideationmedia_commonPharmacologybusiness.industryNeurotoxicityvirus diseasesmedicine.diseaseBenzoxazinesCytochrome P-450 CYP2B6Disease Models AnimalInfectious DiseaseschemistryPharmacogeneticsAlkynesReverse Transcriptase Inhibitorsmedicine.symptomCNSEfavirenzbusinessNeurocognitivePharmacogenetics
researchProduct

Reduction of nevirapine-driven HIV mutations by carbamazepine is modulated by CYP3A activity

2014

Item does not contain fulltext OBJECTIVES: The reduction in mother-to-child transmission of HIV-1 by single-dose nevirapine given at birth onset is achieved at the expense of de novo HIV-1 resistance mutations. In the VITA1 study, single-dose carbamazepine accelerated nevirapine elimination, but the accompanying trend towards fewer de novo HIV-1 mutations was statistically non-significant. METHODS: We investigated if the effect of carbamazepine was confounded by the individual variability in nevirapine metabolism and transport. RESULTS: Nine of 34 (26%) single-dose nevirapine-treated women had one or more nevirapine-associated resistance mutations, compared with 3 of 34 (9%) in the single-d…

Microbiology (medical)NevirapineCYP3AAnti-HIV AgentsHuman immunodeficiency virus (HIV)Mutation MissenseEndogenyHIV InfectionsPharmacologyBiologymedicine.disease_causeChemopreventionPregnancyDrug Resistance ViralmedicineClinical endpointCytochrome P-450 CYP3AHumansPharmacology (medical)NevirapinePharmacologyMutationCYP3A4Cytochrome P-450 CYP3A InducersCarbamazepinelnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Infectious DiseasesCarbamazepineTreatment OutcomeHIV-1Femalemedicine.drug
researchProduct

Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-γ inhibition.

2011

The combined pharmacological approach to the treatment of HIV infection, known as highly active antiretroviral therapy (HAART), has dramatically reduced AIDS-related morbidity and mortality. However, its use has been associated with serious adverse reactions, of which those resulting from mitochondrial dysfunction are particularly widespread. Nucleos(t)ide-reverse transcriptase inhibitors (NRTIs) have long been considered the main source of HAART-related mitochondrial toxicity due to their ability to inhibit Pol-γ, the DNA polymerase responsible for the synthesis of mitochondrial DNA. Nevertheless, accumulating evidence points to a more complex relationship between these organelles and NRTI…

Mitochondrial DNAMitochondrial DiseasesNucleic Acid Synthesis InhibitorDNA polymeraseAnti-HIV Agentsmedicine.medical_treatmentDNA-Directed DNA PolymeraseMitochondrionPharmacologyToxicologyAntiretroviral Therapy Highly ActivemedicineAnimalsHumansNucleic Acid Synthesis InhibitorsPharmacologyProteasebiologyvirus diseasesmedicine.diseaseReverse transcriptaseDNA Polymerase gammaMitochondriaMitochondrial toxicityToxicitybiology.proteinReverse Transcriptase InhibitorsTrends in pharmacological sciences
researchProduct

Molecular dynamics studies on HIV-1 protease: a comparison of the flap motions between wild type protease and the M46I/G51D double mutant

2007

The emergence of drug-resistant mutants of HIV-1 is a tragic effect associated with conventional long-treatment therapies against acquired immunodeficiency syndrome. These mutations frequently involve the aspartic protease encoded by the virus; knowledge of the molecular mechanisms underlying the conformational changes of HIV-1 protease mutants may be useful in developing more effective and longer lasting treatment regimes. The flap regions of the protease are the target of a particular type of mutations occurring far from the active site. These mutations modify the affinity for both substrate and ligands, thus conferring resistance. In this work, molecular dynamics simulations were perform…

Models MolecularGromacs 3.2Anti-HIV AgentsProtein Conformationmedicine.medical_treatmentflap motionMutantCatalysisVirusInorganic ChemistryProtein structureHIV ProteaseHIV-1 proteaseDrug Resistance ViralEnzyme StabilityHIV-1 proteasemedicineHumansComputer SimulationPhysical and Theoretical Chemistrychemistry.chemical_classificationProteasebiologyHIV-1 drug-resistant mutantOrganic ChemistryWild typeActive siteRecombinant ProteinsComputer Science ApplicationsCell biologyEnzymemolecular dynamics simulationAmino Acid SubstitutionComputational Theory and MathematicsBiochemistrychemistryMutationHIV-1biology.protein
researchProduct

Docking and multivariate methods to explore HIV-1 drug-resistance: a comparative analysis

2007

In this paper we describe a comparative analysis between multivariate and docking methods in the study of the drug resistance to the reverse transcriptase and the protease inhibitors. In our early papers we developed a simple but efficient method to evaluate the features of compounds that are less likely to trigger resistance or are effective against mutant HIV strains, using the multivariate statistical procedures PCA and DA. In the attempt to create a more solid background for the prediction of susceptibility or resistance, we carried out a comparative analysis between our previous multivariate approach and molecular docking study. The intent of this paper is not only to find further supp…

Models MolecularMultivariate statisticsMultivariate analysisAnti-HIV AgentsCombined useHuman immunodeficiency virus (HIV)Computational biologyDrug resistanceBiologyLigandsBioinformaticsmedicine.disease_causeHIV ProteaseMolecular descriptorDrug Resistance ViralDrug DiscoverymedicineHumansDOCKINGPhysical and Theoretical ChemistryBinding SitesHIV Protease InhibitorsSettore CHIM/08 - Chimica FarmaceuticaHIV Reverse TranscriptaseComputer Science ApplicationsDRUG RESISTANCEDocking (molecular)Drug DesignMultivariate AnalysisMutationHIV-1Computer-Aided DesignReverse Transcriptase InhibitorsMultivariate statisticalJournal of Computer-Aided Molecular Design
researchProduct

2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.

2004

Several 1,3-thiazolidin-4-ones bearing a 2,6-dihalophenyl group at C-2 and a substituted pyrimidin-2-yl ring at the N-3 were synthesised and evaluated as anti-HIV agents. The results of the in vitro tests showed that some of them were highly effective inhibitors of human immunodeficiency virus type-1 (HIV-1) replication at 10–40 nM concentrations with minimal cytotoxicity. Structure–activity relationship studies revealed that the nature of the substituents at the 2 and 3 positions of the thiazolidinone nucleus had a significant impact on the in vitro anti-HIV activity of this class of potent antiretroviral agents. The compounds had significantly reduced activity against the characteristic N…

NNRTI3-Thiazolidin-4-onesAnti-HIV activity13-Thiazolidin-4-oneNNRTIs; 1; 3-Thiazolidin-4-ones; anti-HIVAnti-HIV Agents1Drug Evaluation PreclinicalMutation MissenseBiologyVirus ReplicationVirusStructure-Activity RelationshipVirologyDrug Resistance ViralmedicineStructure–activity relationshipCytotoxicityPharmacologyReverse-transcriptase inhibitorMolecular Structurevirus diseasesanti-HIVSettore CHIM/08 - Chimica FarmaceuticaMolecular biologyIn vitroReverse transcriptaseThiazolesPyrimidinesViral replicationAmino Acid SubstitutionNNRTIsHIV-1Reverse Transcriptase InhibitorsNucleosidemedicine.drugAntiviral research
researchProduct

A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen

2011

Abstract Background HIV-1 genotypic susceptibility scores (GSSs) were proven to be significant prognostic factors of fixed time-point virologic outcomes after combination antiretroviral therapy (cART) switch/initiation. However, their relative-hazard for the time to virologic failure has not been thoroughly investigated, and an expert system that is able to predict how long a new cART regimen will remain effective has never been designed. Methods We analyzed patients of the Italian ARCA cohort starting a new cART from 1999 onwards either after virologic failure or as treatment-naïve. The time to virologic failure was the endpoint, from the 90th day after treatment start, defined as the firs…

OncologyMaleAdult; Anti-HIV Agents; Cohort Studies; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Proportional Hazards Models; Treatment Failure; Viral LoadHIV InfectionsCohort Studies0302 clinical medicineANTIRETROVIRAL THERAPYMedicineHIV Infection030212 general & internal medicineTreatment Failure0303 health sciencesHealth PolicyMiddle AgedViral Load3. Good healthComputer Science ApplicationsCensoring (clinical trials)CohortCombinationlcsh:R858-859.7Drug Therapy CombinationFemaleViral loadHumanResearch ArticleCartAdultmedicine.medical_specialtyAnti-HIV AgentsHIV-1; antiretroviral therapyHealth InformaticsSettore MED/17 - MALATTIE INFETTIVElcsh:Computer applications to medicine. Medical informatics03 medical and health sciencesDrug TherapyInternal medicineHumansSurvival analysisProportional Hazards Models030306 microbiologybusiness.industryProportional hazards modelAdult; Anti-HIV Agents; Cohort Studies; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Proportional Hazards Models; Treatment Failure; Viral Load; Health Informatics; Health PolicyANTIRETROVIRAL DRUGSAnti-HIV AgentHIVGENOTYPESDiscontinuationRegimenImmunologyProportional Hazards ModelHIV-1Cohort StudiebusinessBMC Medical Informatics and Decision Making
researchProduct

A density functional study of flavonoid compounds with anti-HIV activity.

2005

Abstract Quantum chemical calculations at the DFT/B3LYP theory level, with the 6-31G* basis set, was employed to calculate a set of molecular properties of 26 flavonoid compounds with anti-HIV activity. The correlation between biological activity and structural properties was obtained by using the multiple linear regression method. The model obtained showed not only statistical significance but also predictive ability. We demonstrate in this paper that the anti-HIV activity of compounds can be related with the molecular hydrophobicity (ClogP), the electronegativity ( χ ) and the charges on some key atoms, while that the toxicity can be related with the electronic affinities (EA), ClogP and …

PharmacologyFlavonoidsQuantitative structure–activity relationshipMolecular StructureChemistryStereochemistryAnti-HIV AgentsOrganic ChemistryQuantitative Structure-Activity RelationshipBiological activityGeneral MedicineAffinitiesModels BiologicalElectronegativityPartition coefficientComputational chemistryDrug DiscoveryLinear regressionAtomLymphocytesBasis setEuropean journal of medicinal chemistry
researchProduct